1140859--11/25/2008--AMERISOURCEBERGEN_CORP

related topics
{condition, economic, financial}
{regulation, government, change}
{customer, product, revenue}
{system, service, information}
{regulation, change, law}
{product, liability, claim}
{product, market, service}
{acquisition, growth, future}
{control, financial, internal}
{operation, international, foreign}
{cost, contract, operation}
Intense competition as well as industry consolidations may erode our profit margins. Our results of operations continue to be subject to the risks and uncertainties of inflation in branded pharmaceutical prices and deflation in generic pharmaceutical prices. Declining economic conditions could adversely affect our results of operations and financial condition. Our stock price and our ability to access credit markets may be adversely affected by the current levels of financial market volatility and disruption, which are unprecedented. Our total revenue and results of operations may suffer upon the loss of a significant customer. Our total revenue and results of operations may suffer upon the bankruptcy, insolvency or other credit failure of a significant customer. Our results of operations may suffer upon the bankruptcy, insolvency or other credit failure of a significant supplier. Increasing governmental efforts to regulate the pharmaceutical supply channel may increase our costs and reduce our profitability. The suspension or revocation by the DEA of any of the registrations that must be in effect for our distribution facilities to purchase, store and distribute controlled substances or the refusal by DEA to issue a registration to any such facility that requires such registration may adversely affect our reputation, our business and our results of operations. Legal and regulatory changes reducing reimbursement rates for pharmaceuticals and/or medical treatments or services may reduce our profitability and adversely affect our business and results of operations. The changing United States healthcare environment may negatively impact our business and our profitability. If we fail to comply with laws and regulations in respect of healthcare fraud and abuse, we could suffer penalties or be required to make significant changes to our operations. Our results of operations and financial condition may be adversely affected if we undertake acquisitions of businesses that do not perform as we expect or that are difficult for us to integrate. Our results of operations and our financial condition may be adversely affected by foreign operations. Risks generally associated with our sophisticated information systems may adversely affect our business and results of operations. Risks generally associated with implementation of an enterprise resource planning (ERP) system may adversely affect our business and results of operations or the effectiveness of internal control over financial reporting. Tax legislation initiatives or challenges to our tax positions could adversely affect our results of operations and financial condition.

Full 10-K form ▸

related documents
1140859--11/23/2010--AMERISOURCEBERGEN_CORP
920527--5/23/2008--PSS_WORLD_MEDICAL_INC
920527--5/26/2010--PSS_WORLD_MEDICAL_INC
78749--6/9/2009--AGILYSYS_INC
920527--5/20/2009--PSS_WORLD_MEDICAL_INC
856982--3/10/2010--MERIT_MEDICAL_SYSTEMS_INC
821026--2/26/2010--ANDERSONS_INC
764858--9/27/2007--FOUNTAIN_POWERBOAT_INDUSTRIES_INC
723612--3/1/2006--CENDANT_CORP
29989--2/27/2009--OMNICOM_GROUP_INC
1140859--11/28/2007--AMERISOURCEBERGEN_CORP
97216--2/28/2007--TEREX_CORP
49071--2/20/2009--HUMANA_INC
720671--6/30/2009--HALIFAX_CORP_OF_VIRGINIA
949874--3/12/2009--YOUNG_INNOVATIONS_INC
764401--11/30/2010--INSTEEL_INDUSTRIES_INC
918581--3/6/2008--CIBER_INC
949874--3/14/2006--YOUNG_INNOVATIONS_INC
949874--3/15/2007--YOUNG_INNOVATIONS_INC
949874--3/14/2008--YOUNG_INNOVATIONS_INC
97216--2/27/2008--TEREX_CORP
852426--3/29/2006--PW_EAGLE_INC
320121--5/23/2006--TELOS_CORP
33113--5/12/2009--ENVIRONMENTAL_TECTONICS_CORP
40533--2/19/2010--GENERAL_DYNAMICS_CORP
745394--3/16/2007--LESCO_INC/OH
57139--8/28/2009--LABARGE_INC
822663--3/15/2006--INTER_PARFUMS_INC
97216--5/17/2006--TEREX_CORP
1099800--2/26/2010--Edwards_Lifesciences_Corp